Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-16
2008-11-18
Wilson, James (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
07452892
ABSTRACT:
The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas:including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4and R5are described herein.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5698527 (1997-12-01), Kim
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5990109 (1999-11-01), Chen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6528512 (2003-03-01), Gallagher et al.
patent: 6635626 (2003-10-01), Barrish et al.
patent: 6737085 (2004-05-01), Nishibe et al.
patent: 2004/0063580 (2004-04-01), Kuragano et al.
patent: 196 22 222 (1997-12-01), None
patent: 0 142 146 (1985-05-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 675 714 (1995-10-01), None
patent: 0 818 448 (1998-01-01), None
patent: 0 992 496 (2000-04-01), None
patent: 1 022 272 (2000-07-01), None
patent: 1 333 031 (2003-08-01), None
patent: 2 596 393 (1987-10-01), None
patent: 1 291 417 (1972-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2 304 106 (1997-03-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 2004/009560 (2004-01-01), None
patent: WO2005/049615 (2005-06-01), None
patent: WO2005/063761 (2005-07-01), None
patent: WO2005/063762 (2005-07-01), None
Vippagunta et. al., Advanced Drug Delivery Reviews, 48 (2001) 3-26.
Muccioli, G.G. ; Lambert, D.M., “Latest advances in cannabinoid receptor antagonists and inverse agonists”, Expert Opin. Ther. Patents, vol. 16(10), pp. 1405-1423 (2006).
Aranyos, A. et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers”, J. Am. Chem. Soc., vol. 121, pp. 4369-4378 (1999).
Biller, Scott et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Biller, Scott et al., “Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase”, J. of Medicinal Chemistry, vol. 31(10), pp. 1869-1871 (1988).
Brown, D.J., “Pyrimidines and their Benzo Derivatives”, Comprehensive Heterocyclic Chemistry, vol. 3, Part 2B, pp. 57-142 (1984).
Buback, M. et al., “Diastereoselectivity and Kinetics of Intermolecular Hetero Diels-Alder Reactions under High Pressure. A Significant Pressure-Induced Increase in Stereoselectivity”, Chem. Ber., vol. 122, pp. 1179-1186 (1989).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, Dissertation, Dept Med Chem U of Utah, Abstract, Table of Contents, pp. 16, 17, 40-43,48-51, Summary (1987).
Cocco, M.T. et al., “1,2,4-Triazolo[4,3-c] From 4-Acylhydrazinopyrimidines”, J. Heterocyclic Chem, vol. 29, pp. 1341-1347 (1992).
Colombo, G. et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716”, Life Sciences, vol. 63(8), pp. 113-117 (1998).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration that “Presqualene Pyrophosphate” is an Essential Intermediate on the Path to Squalene”J. of Amer. Chem. Soc., vol. 98(5), pp. 1291-1293 (1976).
DiMarzo, V. et al., “Leptin-regulated endocannabinoids are involved in maintaining food intake” Nature, vol. 410, pp. 822-825 (2001).
Erian, A.W., “The Chemistry of β-Enaminonitriles as Versatile Reagents in Heterocyclic Synthesis”, Chem. Rev., vol. 93, pp. 1991-2005 (1993).
Galiegue, S. et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations”, Eur. J. Biochem., vol. 232, pp. 54-61 (1995).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16(1), pp. 16-30 (1998).
Glass, M., et al., “Cannabinoid Receptors in the Human Brain: A Detailed Anatomical and Quantitative Autoradiographic Study in the Fetal, Neonatal and Adult Human Brain”, Neuroscience, vol. 77(2), pp. 299-318 (1997).
Groziak, M.P., “Six-Membered Ring Systems: Diazines and Benzo Derivatives”, Progress in Heterocyclic Chemistry, vol. 8, pp. 231-254 (1996).
Groziak, M.P., “Six-Membered Ring Systems: Diazines and Benzo Derivatives”, Progress in Heterocyclic Chemistry, vol. 15, pp. 306-338 (2003).
Hamann, B.C. et al., “Sterically Hindered Chelating Alkyl Phosphines provide large rate accelerations in Palladium-Catalyzed Amination of Aryl Iodides, Bromides and Chlorides, and the First Amination of Aryl Tosylates”, J. Am. Chem. Soc., vol. 120, pp. 7369-7370 (1998).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24(4), pp. 425-430 (1999).
Heinisch, G. et al., “Six-Membered Ring Systems: Diazines and Benzo Derivatives”, Progress in Heterocyclic Chemistry, vol. 7, pp. 226-243 (1995).
Hildebrandt, A. et al., “Antiobesity effects of chronic cannabinoid CB1receptor antagonist treatment in diet-induced obese mice”, Eur. J. of Pharmacology, vol. 462, pp. 125-132 (2003).
Hojo, M. et al., “O-N, S-N and N-N exchange reactions at olefinic carbon atoms: Facile Synthetic Method for β-Trifluoroacetylvinylamines”, Tetrahedron Letters, vol. 30(45), pp. 6173-6176 (1989).
Hollenbaugh, D. et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with
Gu Zhengxiang
Mikkilineni Amarendra B.
Murugesan Natesan
Sher Philip M.
Wu Gang
Bristol--Myers Squibb Company
Gibbons Maureen S.
Miano Rosemary M.
Murray Jeffrey H
Wilson James
LandOfFree
Triazolopyrimidine cannabinoid receptor 1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyrimidine cannabinoid receptor 1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyrimidine cannabinoid receptor 1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036516